a KFF analysis of 2023 Part D enrollment data that was published Monday.
The government negotiated with the manufacturers to reduce the price the government will pay to $250 for a month’s supply and in return the companies will have access to the larger patient population. Each patient will pay a $50 copay towards the cost of the medication, but that continue reading …
